{"log_id": 5304247165174803212, "direction": 0, "words_result_num": 50, "words_result": [{"probability": {"variance": 0.010946, "average": 0.944642, "min": 0.600859}, "location": {"width": 248, "top": 202, "height": 28, "left": 226}, "words": "核推日期2009年01月04日"}, {"probability": {"variance": 1e-06, "average": 0.999357, "min": 0.997598}, "location": {"width": 340, "top": 228, "height": 43, "left": 435}, "words": "培门冬酶注射液说明书"}, {"probability": {"variance": 6e-06, "average": 0.998519, "min": 0.989242}, "location": {"width": 389, "top": 275, "height": 40, "left": 408}, "words": "请仔细阅读说明书并在医师指导下使用"}, {"probability": {"variance": 1.5e-05, "average": 0.996613, "min": 0.988623}, "location": {"width": 109, "top": 319, "height": 27, "left": 232}, "words": "【药品名称】"}, {"probability": {"variance": 0.019769, "average": 0.953832, "min": 0.487715}, "location": {"width": 244, "top": 348, "height": 30, "left": 264}, "words": "通用名称:培门冬酶注射液"}, {"probability": {"variance": 8.6e-05, "average": 0.992818, "min": 0.974827}, "location": {"width": 128, "top": 381, "height": 23, "left": 265}, "words": "英文名称:Pe"}, {"probability": {"variance": 0.020872, "average": 0.780134, "min": 0.635662}, "location": {"width": 89, "top": 384, "height": 17, "left": 454}, "words": " se Injectioi"}, {"probability": {"variance": 0.000697, "average": 0.98188, "min": 0.921604}, "location": {"width": 117, "top": 412, "height": 25, "left": 265}, "words": "汉语拼音:Pe"}, {"probability": {"variance": 0.017847, "average": 0.807349, "min": 0.673757}, "location": {"width": 74, "top": 412, "height": 18, "left": 482}, "words": " ei Zhuche"}, {"probability": {"variance": 0.001212, "average": 0.977517, "min": 0.917373}, "location": {"width": 111, "top": 443, "height": 26, "left": 234}, "words": "【成份】"}, {"probability": {"variance": 0.012342, "average": 0.941891, "min": 0.455344}, "location": {"width": 823, "top": 461, "height": 38, "left": 269}, "words": "本品主要成份为培门冬酶,培门冬酶为左旋门冬胺酶与一定数量的活化态聚乙二醇(PEG)500"}, {"probability": {"variance": 0.012673, "average": 0.964827, "min": 0.464368}, "location": {"width": 721, "top": 494, "height": 37, "left": 228}, "words": "通过共价结食而制得的酶制剂。本所用起始原料门冬酰胺酶生产菌为大肠杆菌(E"}, {"probability": {"variance": 0.001449, "average": 0.968404, "min": 0.914849}, "location": {"width": 97, "top": 536, "height": 22, "left": 244}, "words": "性状】"}, {"probability": {"variance": 0.004734, "average": 0.967149, "min": 0.735925}, "location": {"width": 282, "top": 561, "height": 31, "left": 270}, "words": "本品为无色澄明液体,微有乳光"}, {"probability": {"variance": 0.000365, "average": 0.976942, "min": 0.953427}, "location": {"width": 106, "top": 597, "height": 23, "left": 237}, "words": "【适应症】"}, {"probability": {"variance": 0.019043, "average": 0.942518, "min": 0.501133}, "location": {"width": 437, "top": 620, "height": 32, "left": 268}, "words": "本晶可用于儿童急性淋巴细胞白血病患者线治疗"}, {"probability": {"variance": 0.001044, "average": 0.982641, "min": 0.820929}, "location": {"width": 823, "top": 644, "height": 39, "left": 270}, "words": "与左旋门冬酰胺酶一样,本品一般被用于联合化疗,推荐与长春新碱,泼尼松和柔红霉素联合使用"}, {"probability": {"variance": 0.022899, "average": 0.935093, "min": 0.415719}, "location": {"width": 321, "top": 684, "height": 30, "left": 229}, "words": "本品目前尚无单药使用临研究信息"}, {"probability": {"variance": 0.001442, "average": 0.957547, "min": 0.901281}, "location": {"width": 108, "top": 719, "height": 25, "left": 236}, "words": "【规格】"}, {"probability": {"variance": 0.018557, "average": 0.898853, "min": 0.528659}, "location": {"width": 120, "top": 753, "height": 21, "left": 267}, "words": "5ml:3750IU"}, {"probability": {"variance": 0.000903, "average": 0.983477, "min": 0.916531}, "location": {"width": 106, "top": 781, "height": 25, "left": 237}, "words": "【用法用量】"}, {"probability": {"variance": 0.007429, "average": 0.970505, "min": 0.520521}, "location": {"width": 696, "top": 802, "height": 38, "left": 269}, "words": "用量:联食使用时,本品推荐剂量为2500IU/m2,肌肉注射,每14天给药一次"}, {"probability": {"variance": 0.009515, "average": 0.97593, "min": 0.362934}, "location": {"width": 833, "top": 832, "height": 37, "left": 270}, "words": "用法:肌肉注射。在单一部位注射给药应少于2ml;如需要使用的体积超过2ml,则应在多个"}, {"probability": {"variance": 2.2e-05, "average": 0.996992, "min": 0.988882}, "location": {"width": 78, "top": 876, "height": 24, "left": 234}, "words": "部位注射"}, {"probability": {"variance": 0.016296, "average": 0.947001, "min": 0.52046}, "location": {"width": 811, "top": 894, "height": 38, "left": 272}, "words": "使用注意:如果出现严重急性过敏反应,则需立即停止使用本晶。给予抗组胺药物、肾上腺素"}, {"probability": {"variance": 0.009705, "average": 0.973486, "min": 0.592033}, "location": {"width": 326, "top": 933, "height": 32, "left": 231}, "words": "氧气和静脉内注射类固醉等救治措施"}, {"probability": {"variance": 0.004468, "average": 0.983775, "min": 0.560918}, "location": {"width": 834, "top": 952, "height": 47, "left": 270}, "words": "只要溶液和容器许可,注射用药品都应该在使用前通过肉眼检查颗粒物质,混浊和变色。如发现"}, {"probability": {"variance": 0.000235, "average": 0.992326, "min": 0.936142}, "location": {"width": 381, "top": 995, "height": 35, "left": 233}, "words": "溶液中有微粒、浑浊、污点,须扔掉该药品"}, {"probability": {"variance": 0.000592, "average": 0.990529, "min": 0.853925}, "location": {"width": 827, "top": 1018, "height": 43, "left": 271}, "words": "如果本品已经被冷结成冰、或室温放置了48小时以上、或振摇、或剧烈的搅动过,则不能再使用"}, {"probability": {"variance": 0.000177, "average": 0.992979, "min": 0.963246}, "location": {"width": 110, "top": 1064, "height": 27, "left": 239}, "words": "【不良反应】"}, {"probability": {"variance": 0.00014, "average": 0.994969, "min": 0.935958}, "location": {"width": 834, "top": 1080, "height": 45, "left": 272}, "words": "因为临床试验在非同等条件下进行,以下临床试验观察到的不良反应发生率不能与其他临床试验"}, {"probability": {"variance": 0.014598, "average": 0.958228, "min": 0.4889}, "location": {"width": 790, "top": 1113, "height": 40, "left": 236}, "words": "不良反应发生率进行直接比较,而也不能代表本品临床实际应用所观察的不良反应发生率"}, {"probability": {"variance": 4.8e-05, "average": 0.996397, "min": 0.97826}, "location": {"width": 163, "top": 1155, "height": 27, "left": 274}, "words": "国外临床研究经验"}, {"probability": {"variance": 4.7e-05, "average": 0.995543, "min": 0.980037}, "location": {"width": 239, "top": 1184, "height": 30, "left": 274}, "words": "美国 Enzon公司生产的On"}, {"probability": {"variance": 6.8e-05, "average": 0.994699, "min": 0.969352}, "location": {"width": 536, "top": 1174, "height": 33, "left": 570}, "words": "也系左旋门冬酰胺酶经PEG修饰制得的酶制剂(所用起始原料"}, {"probability": {"variance": 0.001449, "average": 0.990927, "min": 0.755859}, "location": {"width": 870, "top": 1202, "height": 45, "left": 236}, "words": "门冬酰胺酶为 Merk Sharp& Dohme公司生产,生产菌为大肠杆菌)。其临床试验中最常见的不良反应有"}, {"probability": {"variance": 0.004904, "average": 0.982323, "min": 0.543462}, "location": {"width": 841, "top": 1235, "height": 41, "left": 236}, "words": "过敏反应,高血糖痘,中枢神经系统(CNS)血栓,凝血功能异常,转氨酶升高,高胆红素血症等"}, {"probability": {"variance": 0.005194, "average": 0.976121, "min": 0.718147}, "location": {"width": 284, "top": 1274, "height": 36, "left": 275}, "words": "急性淋巴细胞白血病的一线治疗"}, {"probability": {"variance": 0.002705, "average": 0.987961, "min": 0.672566}, "location": {"width": 833, "top": 1298, "height": 41, "left": 277}, "words": "下列不良反应资料从 Caspar2项临床研究中获得,研究内容为标危的急性淋巴性白血病患者接"}, {"probability": {"variance": 0.006586, "average": 0.976386, "min": 0.517025}, "location": {"width": 864, "top": 1330, "height": 43, "left": 237}, "words": "受 Caspar治疗,其中 Oncaspar作为多药联用一线治疗方案中的一个组份。研究1是一个随机(1:"}, {"probability": {"variance": 0.001316, "average": 0.98354, "min": 0.835427}, "location": {"width": 869, "top": 1361, "height": 44, "left": 241}, "words": "),阳性药对照的研究,包括118例患者,平均年龄为4.7岁(1.19岁),其中54%是男性,65%"}, {"probability": {"variance": 0.001325, "average": 0.988054, "min": 0.758151}, "location": {"width": 872, "top": 1394, "height": 43, "left": 239}, "words": "为白种人,14%为西班牙人种,8%为黑人,8%为亚洲人,6%为其他人种。研究1中59例患者随机"}, {"probability": {"variance": 0.006136, "average": 0.963885, "min": 0.788739}, "location": {"width": 123, "top": 1440, "height": 29, "left": 239}, "words": "分在不同的O"}, {"probability": {"variance": 0.000672, "average": 0.984812, "min": 0.885384}, "location": {"width": 361, "top": 1430, "height": 35, "left": 427}, "words": "治疗组,48例(81%)接受3个剂量的O"}, {"probability": {"variance": 0.003121, "average": 0.975935, "min": 0.784519}, "location": {"width": 228, "top": 1429, "height": 26, "left": 869}, "words": "6例(10%)接受2个剂量"}, {"probability": {"variance": 0.003336, "average": 0.971188, "min": 0.806276}, "location": {"width": 567, "top": 1462, "height": 38, "left": 237}, "words": "4名(7%)接受1个剂量,1例患者(2%)没有接受指定的治疗"}, {"probability": {"variance": 0.001119, "average": 0.987079, "min": 0.836142}, "location": {"width": 542, "top": 1493, "height": 36, "left": 278}, "words": "研究2是一个正在进行的多因素设计的临床研究,患者接受O"}, {"probability": {"variance": 5.1e-05, "average": 0.995203, "min": 0.977669}, "location": {"width": 225, "top": 1490, "height": 26, "left": 887}, "words": "治疗,其中 Oncaspar作为"}, {"probability": {"variance": 0.001475, "average": 0.98992, "min": 0.75348}, "location": {"width": 870, "top": 1519, "height": 43, "left": 242}, "words": "不同的多药联用一线治疗方案中的一个组份。总共2770名患者而获得中期安全性数据。受试者的中位"}, {"probability": {"variance": 0.000315, "average": 0.991438, "min": 0.899075}, "location": {"width": 871, "top": 1552, "height": 40, "left": 241}, "words": "年龄为4岁(1~10岁),其中55%是男性,68%为白种人,18%为西班牙人种,4%为黑人,3%为亚"}], "language": 3}